tiprankstipranks
Advertisement
Advertisement

ABEO Stock Latest News

Abeona Shareholders Back Board, Equity Plan at Meeting
Company AnnouncementsAbeona Shareholders Back Board, Equity Plan at Meeting
4d ago
8K
ABEO
Abeona Therapeutics announces resignation of board member
PremiumCompany Announcements
Abeona Therapeutics announces resignation of board member
4d ago
8K
ABEO
Abeona Therapeutics Updates Investor Presentation Under Regulation FD
PremiumCompany Announcements
Abeona Therapeutics Updates Investor Presentation Under Regulation FD
6d ago
8K
ABEO
Abeona Advances ABO-701 T-Cell Therapy Toward IND
PremiumCompany Announcements
Abeona Advances ABO-701 T-Cell Therapy Toward IND
12d ago
8K
ABEO
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
PremiumCompany Announcements
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
27d ago
ABEO
Abeona Therapeutics Signals Strong Early ZEVASKYN Launch
PremiumCompany AnnouncementsAbeona Therapeutics Signals Strong Early ZEVASKYN Launch
1M ago
ABEO
Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)
Premium
The Fly
Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)
1M ago
ABEO
ABEO Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ABEO Upcoming Earnings Report: What to Expect?
1M ago
ABEO
Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair
PremiumCompany Announcements
Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair
2M ago
8K
ABEO
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
PremiumCompany Announcements
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
3M ago
8K
ABEO
Early-Stage ZEVASKYN Momentum and Attractive Economics Underscore Abeona’s Undervalued Growth Potential and $20 Buy Rating
PremiumRatings
Early-Stage ZEVASKYN Momentum and Attractive Economics Underscore Abeona’s Undervalued Growth Potential and $20 Buy Rating
3M ago
ABEO
Abeona Therapeutics Balances Big Windfall With Slow Ramp
PremiumCompany Announcements
Abeona Therapeutics Balances Big Windfall With Slow Ramp
3M ago
ABEO
Abeona Therapeutics price target lowered to $20 from $27.50 at Alliance Global
PremiumThe FlyAbeona Therapeutics price target lowered to $20 from $27.50 at Alliance Global
3M ago
ABEO
Options Volatility and Implied Earnings Moves Today, March 17, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves Today, March 17, 2026
3M ago
ASO
TME
Abeona Therapeutics reports 2025 EPS $1.01 vs. ($1.55) last year
Premium
The Fly
Abeona Therapeutics reports 2025 EPS $1.01 vs. ($1.55) last year
3M ago
ABEO
Options Volatility and Implied Earnings Moves This Week, March 16 – March 20, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, March 16 – March 20, 2026
3M ago
M
MU
ABEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ABEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
ABEO
Early ZEVASKYN Launch Traction and Robust Reimbursement Support Abeona Buy Rating and $20 Target
PremiumRatings
Early ZEVASKYN Launch Traction and Robust Reimbursement Support Abeona Buy Rating and $20 Target
3M ago
ABEO
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
PremiumCompany Announcements
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
3M ago
8K
ABEO
Abeona Therapeutics provides business update on momentum in Zevaskyn launch
PremiumThe FlyAbeona Therapeutics provides business update on momentum in Zevaskyn launch
3M ago
ABEO
3 Best Stocks to Buy Today, 2/3/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 2/3/2026, According to Top Analysts
4M ago
ABEO
AFRM
Abeona Therapeutics: Advancing UX111 Toward First-to-Market Approval and Scaling ZEVASKYN Launch to Near-Term Profitability
Premium
Ratings
Abeona Therapeutics: Advancing UX111 Toward First-to-Market Approval and Scaling ZEVASKYN Launch to Near-Term Profitability
4M ago
ABEO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >